Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 581-585

  Yilmaz, E ^b   Akalin, Halis ^a   Ozbey S ^b   Kordan, Y ^b   Sinirtas M ^b   Gurcuoglu E ^b   Ozakin C ^b   Heper, Y ^b   Mistik, R ^b   Helvaci, S ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b NONE

Author keywords

Quinolones; Urinary tract infection; UTI risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMINOPENICILLIN; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; DRUG USE; EMPIRICISM; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT PLANNING; URETHRAL CATHETER; URINARY TRACT INFECTION; URINE CULTURE; UROLITHIASIS; UROLOGIC SURGERY;

EID: 57049110575     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.581     Document Type: Article

References (22)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
2. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
3. Rodriguez-Bano J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms. Clin Infect Dis 2006; 42: 935-7.
4. Paterson DL, Yu VL. Extended-spectrum beta-lactamases: a call for improved detection and control. Clin Infect Dis 1999; 29: 1419-22.
5. Paterson DL, Ko W-C, Gottberg AV, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
6. Endimiani A, Luzzaro F, Perili M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004; 38: 243-51.
7. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34: 135-46.
8. Naber KG, Bishop MC, Bjerklund TE, et al. Guidelines on the management of urinary and male genital tract infections. Eur Assoc Urol, 2006.
9. CTX-M genes. Clin Infect Dis 2004; 38: 1736-41.
10. Pitout JDD, Gregson DB, Church DL, Elsayed S, Laupland. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary Health Region. J Clin Microbiol 2005; 43: 2844-9.
11. Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
12. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163-7.
13. Arslan H, Kurt Azap Ö, Ergönül Ö, Timurkaynak F on behalf of the urinary tract infection study group. Risk factors for ciprofloxacin resistance among Escherichia coli starins isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914-8.
14. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006;57: 780-3.
15. Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua MLM, Arnador C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase producing Escherichia coli. Urology 2006; 68:1169-74.
16. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone, 2005:773-805.
17. Hyle EP, Adam DL, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum-beta-lactamase producing Enterobacteriaceae. Arch Intern Med 2005;165:1375-80.
18. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M Era: a new clinical challenge. Clin Infect Dis 2006;43:1407-14.
19. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008; 14(Suppl 1): 169-74.
20. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006;54:231-6.
21. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-5.
22. Pullukcu H, Tasbakan M, Sipahi OR et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5.